Authors
1 Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan; Skin and Stem Cell Research Center, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran
2 Skin and Stem Cell Research Center, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran
3 Department of Pharmacology, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: Leishmaniasis is still one of the endemic parasitic infections in many countries comprising Iran. During the past decades, several medical and surgical approaches have been applied and studied to achieve the best option to treat the cutaneous leishmaniasis in Iran and the world. This study was carried out to evaluate the effect of topical Achilles millefolium in conjunction with intralesional glucantime on acute cutaneous leishmanial lesions.
Materials and Methods: sixty patients with confirmed acute cutaneous leishmaniasis were recruited in the study. Patients were randomly allocated into two groups to receive twice daily topical gel of Achilles millefolium 5% (containing 5% poly phenol) (group A) or placebo (group B) for four weeks along with weekly injection of intralesional Glucantime.
Results: There was no significant difference between the two groups according to age, gender, and duration of the disease. Also, there was no significant difference in complete and relative cure rates between the two groups (P = 0.35) using Visual Analog Scale (VAS). Application site reactions were occurred in 12 patients including redness in 8 cases in group-A and 2 cases in group-B, severe itching in one case in group-A and increasing wound secretion in another case in group-A (P = 0.014).
Conclusions: Given the result of the present study, there is no significant difference in cure rates of lesions between yarrow and placebo topical gels as an adjuvant drugs with intralesional glucantime in treatment of acute cutaneous leishmanial lesions.
Keywords
1. | Klaus SN, Frankenburg S, Ingber A. Epidemiology of cutaneous leishmaniasis. Clin Dermatol 1999;17:257-60. |
2. | Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001;95:239-43. |
3. | Herwaldt BL. Leishmaniasis. Lancet 1999;354:1191-9. |
4. | Bari AU. Clinical spectrum of cutaneous leishmaniasis: An overview from Pakistan. Dermatol Online J. 2012;18:4. |
5. | Sousa Ade Q, Parise ME, Pompeu MM, Coehlo Filho JM, Vasconcelos IA, Lima JW, et al. Bubonic leishmaniasis: A common manifestation of Leishmania (Viannia) braziliensis infection in Ceara, Brazil. Am J Trop Med Hyg 1995;53:380-5. |
6. | Soto JM, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, Padilla JR, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): Phase 2 pilot study. Am J Trop Med Hyg 2002;66:147-51. |
7. | Barral A, Guerreiro J, Bomfim G, Correia D, Barral-Netto M, Carvalho EM. Lymphadenopathy as the first sign of human cutaneous infection by Leishmania braziliensis. Am J Trop Med Hyg 1995;53:256-9. |
8. | Luize PS, Tiuman TS, Morello LG, Maza PK, Ueda-Nakamura T, Dias Filho BP, et al. Effects of medicinal plant extracts on growth of Leishmania (L.) amazonensis and Trypanosoma cruzi. Rev Bras Cienc Farm 2005;41:85-94. |
9. | Berman JD. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997;24:684-703. |
10. | Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des 2002;8:319-42. |
11. | Reithinger R, Mohsen M, Wahid M, Bismullah M, Quinnell RJ, Davies CR, et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: A randomized, controlled trial. Clin Infect Dis 2005;40:1148-55. |
12. | Rak Cheev AP, Chistiakova IA. The successful treatment of cutaneous leishmaniasis with an argon laser. Veston Dermatol Venerol 1989;12:53-5. |
13. | Lerner EA, Grevelink SA. Leishmaniasis. In: Arndt KA, Leboil PE, Robinson JK, Wintroub BU, editors. Cutaneous medicine and surgery. I st ed. Philadelphia: W.B Saunders company, 1996: p.1163-70. |
14. | Vardy D, Baranholz YC. Topical amphotericin B for cutaneous leishmaniasis. Arch Dermatol 1997;135:856-7. |
15. | Zerehsaz F, Salmanpour R, Handjani F. A double-blind randomized clinical trial of a topical herbal extract (ZHE) vs systemic meglumine antimoniate for treatment of cutaneous leishmaniasis in Iran. Int J Dermatol 1999;38:610-2. |
16. | Dowlati Y. Cutaneous leishmaniasis: Clinical aspect. Clin Dermatol 1997;14:425-31. |
17. | Fournot A. Effect of natural naphthoquinones in Balb/c mice infected with Leishmania amazonensis and Leishmania venezulensis. Trop Med Parasitol 1992;43:219-22. |
18. | Nilforoushzadeh MA, Shirani-Bidabadi L, Zolfaghari-Baghbaderani A, Saberi S, Siadat AH, Mahmoudi M. Comparison of Thymus vulgaris (Thyme), Achillea millefolium (Yarrow) and propolis hydroalcoholic extracts versus systemic glucantime in the treatment of cutaneous leishmaniasis in balb/c mice. J Vector Borne Dis 2008;45:301-6. |
19. | Nilforoushzadeh MA, Jaffary F, Moradi SH, Derakhshan R, Haftbaradaran E. Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutaneous leishmaniasis. BMC Complement Altern Med 2007;7:13-17. |
20. | Moheb Ali M, Chenari A, Nazari M. The efficacy of Cassia fistula on Leishmaniasis major ulcer in Balb/c mice. Pajoohandeh J Spring 1999;13:9-14. |
21. | Siadat AH, Shirani Bidabadi L, Zolfaghari Baghbaderani A, Saberi S, Nilforoshzadeh MA, Jooya A, et al. Topical combination (azithromycin, fluconazole, metronodazole) and systemic glucantime treatments for cutaneous leishmaniasis. J Cell Tissue Res 2007;7:1137-40. |
22. | Jaffary F, Nilforoushzadeh MA, Tavakoli N, Zolfaghari B, Shahbazi F. Contact reactions due to Achillea millefolium gel used in the treatment of cutaneous leishmaniasis. Elec J Pharmacol Ther 2011;4:5-7. |
23. | Mark KA, Brancaccio RR, Soter NA, Cohen DE. Allergic contact and photoallergic contact dermatitis to plant and pesticide allergens. Arch Dermatol 1999;135:67-70. |
24. | Final report on the safety assessment of yarrow (Achillea Millefolium) Extract. Int J Toxicol 2001;20 Suppl. 2:79-84. |